Blueprint Medicines News

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

09.06.18	An Ear To The Pharma: 8 Stocks To Watch (CMRX, CRBP, KPTI, VRX…) (RTTNews)
04.06.18	Blueprint Medicines and CStone Pharmaceuticals Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Avapritinib, BLU-554 and BLU-667 in Greater China (PR Newswire)
31.05.18	Blueprint Medicines to Present at Upcoming Investor Conferences in June (PR Newswire)
29.05.18	Harvard-Incubated Expercoin Protocol to Launch a Network of Decentralized Learning Economies on the Blockchain (PR Newswire)
17.05.18	Blueprint Medicines Announces Data Presentations at Upcoming ASCO and EHA Meetings Supporting Plans for Rapid Development of Avapritinib in Patients with Gastrointestinal Stromal Tumors and... (PR Newswire)
02.05.18	Blueprint Medicines Reports First Quarter 2018 Financial Results (PR Newswire)
25.04.18	Blueprint Medicines to Report First Quarter 2018 Financial Results on Wednesday, May 2, 2018 (PR Newswire)
17.04.18	CLDX Disappoints Investors, ASNS Awaits Data In 2H18, BPMC Fails To Make A Mark (RTTNews)
15.04.18	Blueprint Medicines Publication in Cancer Discovery Highlights Preclinical and Clinical Proof-of-Concept Data for Highly Selective RET Inhibitor BLU-667 (PR Newswire)
15.04.18	Blueprint Medicines Announces Proof-of-Concept Data for Highly Selective RET Inhibitor BLU-667 from Phase 1 ARROW Clinical Trial in Patients with RET-Altered Solid Tumors (PR Newswire)
08.04.18	An Ear To The Pharma: 9 Stocks To Watch This Week (SELB, AGLE, BPMC, MNOV…) (RTTNews)
14.03.18	Blueprint Medicines to Present Proof-of-Concept Data from Ongoing Phase 1 Clinical Trial of BLU-667 in Patients with RET-Altered Solid Tumors in a Clinical Trials Plenary Session at AACR Annual... (PR Newswire)
06.03.18	Blueprint Medicines to Present at Cowen and Company 38th Annual Health Care Conference (PR Newswire)
21.02.18	Blueprint Medicines Reports Fourth Quarter and Full Year 2017 Financial Results (PR Newswire)
14.02.18	Blueprint Medicines to Report Fourth Quarter and Full Year 2017 Financial Results on Wednesday, February 21, 2018 (PR Newswire)
13.12.17	ADRO Dumps CRS-207, Another Win For CoolSculpting, FDA Expands GSK's Nucala Use (RTTNews)
12.12.17	ARGX Soars, SNSS Catches Eyes, BPMC, BLUE Turn Heads, FDA Nod For SNNA (RTTNews)
11.12.17	Watch Out For BLUE, BPMC, GBT, KURA, KDMN, SYRS Today (RTTNews)
10.12.17	Blueprint Medicines Announces New Data from Ongoing Phase 1 Clinical Trial of Avapritinib (BLU-285) in Patients with Advanced Systemic Mastocytosis Showing Evidence of Strong Clinical Activity (PR Newswire)
05.12.17	ASH: BPMC To Make A Mark; FATE So Far, So Good; Watch Out For SYRS, BIVV (RTTNews)
30.11.17	Merrimack Announces Appointment of George Demetri, M.D., to Board of Directors (PR Newswire)
10.11.17	Blueprint Medicines Announces New Data from Ongoing Phase 1 Clinical Trial of BLU-285 in Patients with Advanced Gastrointestinal Stromal Tumors Showing Strengthened Clinical Activity across... (PR Newswire)
08.11.17	Blueprint Medicines to Present at Jefferies Global Healthcare Conference (PR Newswire)
03.11.17	ABUS Is Abuzz... (RTTNews)
02.11.17	Busy Year Awaits FLKS, Mark Your Calendar For BPMC Data, CLLS Loses Steam (RTTNews)
01.11.17	Blueprint Medicines Announces Publication of BLU-285 Translational Data (PR Newswire)
01.11.17	Blueprint Medicines to Present Updated Data from Ongoing Phase 1 Clinical Trial of BLU-285 in Patients with Advanced Systemic Mastocytosis in Plenary Scientific Session at 59th ASH Annual Meeting... (PR Newswire)
31.10.17	Blueprint Medicines Reports Third Quarter 2017 Financial Results (PR Newswire)
24.10.17	Blueprint Medicines to Report Third Quarter 2017 Financial Results on Tuesday, October 31, 2017 (PR Newswire)
10.10.17	Blueprint Medicines Announces Appointment of Christopher Murray, Ph.D. as Senior Vice President, Technical Operations (PR Newswire)
14.09.17	TTOO Catches Investors' Eyes, SIEN Shaping Up, AGTC Slips Into Red (RTTNews)
11.09.17	New Hope For AZN's Old Drug, More About BMY's Opdivo, IMDZ On Watch (RTTNews)
10.09.17	Blueprint Medicines Announces New Data from Ongoing Phase 1 Clinical Trial of BLU-554 in Patients with Advanced Hepatocellular Carcinoma (PR Newswire)
06.09.17	Blueprint Medicines to Present at Morgan Stanley 15th Annual Global Healthcare Conference (PR Newswire)
23.08.17	Gainers & Losers Of Aug.22: OVID, SNNA, BPMC, ABIO, TOCA... (RTTNews)
22.08.17	FDA Approves IRWD's Gout Drug, It's A Thumbs Up For ALXN In EU, CRME Crushed (RTTNews)
21.08.17	Blueprint Medicines to Present Updated Data from Ongoing Phase 1 Clinical Trial of BLU-554 in Patients with Advanced Hepatocellular Carcinoma at ESMO 2017 Congress and 11th ILCA Annual Conference (PR Newswire)
14.08.17	Stock Performance Review on Biotech Industry -- Blueprint Medicines, Calithera Biosciences, Concordia Intl., and Cytokinetics (PR Newswire)
03.08.17	Blueprint Medicines to Present at Upcoming Investor Conferences in August (PR Newswire)
02.08.17	Blueprint Medicines Reports Second Quarter 2017 Financial Results (PR Newswire)
27.07.17	Blueprint Medicines to Evaluate Opportunities to Advance Rare Disease Discovery Program in Fibrodysplasia Ossificans Progressiva Following Discontinuation of Collaboration with Alexion (PR Newswire)
26.07.17	Blueprint Medicines to Report Second Quarter 2017 Financial Results on Wednesday, August 2, 2017 (PR Newswire)
06.07.17	Gainers & Losers Of July 5: CALA, NVRO, BPMC, KMPH, FLDM... (RTTNews)
05.06.17	Blueprint Medicines Announces New Phase 1 Clinical Data for BLU-285 in Advanced Gastrointestinal Stromal Tumors and Plans to Pursue Expedited Development in Patients with a PDGFRα D842V Mutation (PR Newswire)
18.05.17	SNDX Rises On Entinostat Data, Kalydeco Gets FDA Nod, Concert Fails To Enthrall (RTTNews)
17.05.17	Blueprint Medicines to Present New Data from Ongoing Phase 1 Clinical Trial of BLU-285 in Patients with Advanced Gastrointestinal Stromal Tumors at 2017 ASCO Annual Meeting (PR Newswire)
03.05.17	Blueprint Medicines Reports First Quarter 2017 Financial Results (PR Newswire)
26.04.17	Blueprint Medicines to Report First Quarter 2017 Financial Results on Wednesday, May 3, 2017 (PR Newswire)
04.04.17	Blueprint Medicines Announces Closing of Public Offering and Full Exercise of Option to Purchase Additional Shares of Common Stock (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Logitech Intl	79.88	2.70 %	K V
Roche Hldg G	264.40	2.68 %	K V
Lonza Grp	554.20	2.29 %	K V
Swiss Re	134.85	1.70 %	K V
Novartis	90.39	1.61 %	K V
ABB	49.48	-0.26 %	K V
Geberit	513.60	-0.35 %	K V
Sika	216.90	-0.37 %	K V
Kuehne+Nagel Int	208.50	-0.43 %	K V
Holcim	88.08	-0.45 %	K V

mehr

Portfolioname Watchlistname
Portfolio
Name
Typ
Valor / ISIN
Börse
Anzahl
Aktueller Kurs
Kurszeit
Kaufpreis
Kaufdatum
Kaufwert	CHF
	Hinzufügen Speichern

Nachrichten zu Blueprint Medicines Corp

Aktien Top/Flop

Meistgelesene Nachrichten